Clinical Trial

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2022-08-01; most recent amendment 2026-03-11.
Status change: Recruiting → Active, Not Recruiting 2026-03-11
Status change: Not Yet Recruiting → Recruiting 2022-11-10
Trial Details
NCT Number NCT05484622
Lead Sponsor Institut de Recherches Internationales Servier
Collaborators: Merck Sharp & Dohme LLC
Conditions Astrocytoma, Oligodendroglioma
Enrollment 60 participants
Start Date 2023-01-20
Primary Completion 2026-02-12 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-12